FibroGen, Inc.
United States
206 articles with FibroGen, Inc.
-
FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
2/27/2023
FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen’s 43rd Annual Health Care Conference to be held in Boston on March 5 - 8, 2023.
-
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
2/27/2023
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2022 and provided an update on the company’s recent developments.
-
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
2/17/2023
FibroGen, Inc. will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close.
-
FibroGen to Present at SVB Securities Global Biopharma Conference
2/2/2023
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16 at 3:40 PM Eastern Time.
-
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
11/28/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8, at 1:05 PM Eastern Time.
-
FibroGen Reports Third Quarter 2022 Financial Results
11/7/2022
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2022 and provided an update on the company’s recent developments.
-
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
11/7/2022
FibroGen, Inc. announced a royalty monetization financing with NovaQuest Capital Management that will result in proceeds to FibroGen in the amount of $50 million, bringing non-dilutive capital to drive innovation and growth.
-
FibroGen to Participate at Stifel 2022 Healthcare Conference
11/1/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY taking place on November 15, at 1:50 PM Eastern Time.
-
FibroGen to Report Third Quarter 2022 Financial Results
10/24/2022
FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close.
-
FibroGen Reports Second Quarter 2022 Financial Results
8/8/2022
FibroGen, Inc. reported financial results for the second quarter 2022 and provided an update on the company’s recent developments.
-
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
6/8/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for LELANTOS-2, a Phase 3 clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy (DMD).
-
FibroGen to Present at Jefferies Healthcare Conference
5/26/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT.
-
FibroGen to Report First Quarter 2022 Financial Results
4/25/2022
FibroGen, Inc. will announce its first quarter 2022 financial results on Monday, May 9 after the market close.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
4/20/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for ZEPHYRUS-1, the first of two Phase 3 clinical studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease.
-
FibroGen is tangled up in a Securities Class Action Litigation and Derivative Litigation concerning clinical trial data for its drug Roxadustat.
-
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
2/28/2022
FibroGen, Inc. reported financial results for the fourth quarter and full year 2021 and provided an update on the company’s recent developments.
-
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
2/14/2022
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close.
-
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
2/4/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST.
-
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
1/4/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13.